

Clinical Trials in HK – Lung Cancer

No	Institution	Trial name	Cancer Site	Experimental Treatment Agent	Key Eligibility Criteria	Study Coordinator Contact	Status
1	PYNEH	A Single-arm Phase II Study to Determine the Efficacy of Preemptive Local Ablative Therapy to Residual Metabolic Active Oligo-metastases in Those EGFR Mutation Positive Non-small Cell Lung Cancer Patients Who Have Achieved a Good Partial Response With First-line EGFR TKI [ATOM]	Lung	Radiation: preemptive local ablative therapy	<ol style="list-style-type: none"> 1. NSCLC 2. Activating EGFR Mutation 3. Achieved PR with TKI 	Christine Tse Mandy Wong 2595 4183	Open
2	PYNEH	A Phase III, Double-blind, Randomized, Placebo-controlled Multi-centre, Study to Assess the Efficacy and Safety of AZD9291 Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage IB-III A Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy [ADAURA]	Lung	AZD9291	Stage IB-III A Non-small Cell Lung Carcinoma	Christine Tse Mandy Wong 2595 4183	Open
3	PWH	A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations	Lung	Lorlatinib	Website: https://clinicaltrials.gov/ct2/show/NCT01970865?recr=Open&spons=Pfizer&cntry1=ES%3AHK&rank=6	/	Active, not recruiting

4	QEH	A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo as Maintenance Therapy in Subjects with Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) after Completion of Platinum-based First Line Chemotherapy CA209- 451	Lung	Nivolumab, Ipilimumab, Placebo	<ol style="list-style-type: none"> 1. Extensive stage of small cell lung carcinoma 2. Received 4 cycles of platinum-based, first-line chemo with response CR, PR, SD 3. Minimum 10 slides of Tumor biopsy 	Leann 3506 2851	Open
5	QEH	An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor <i>NTRK1/2/3, ROS1, or ALK</i> Gene Rearrangements RXDX-101-02	Lung	Single arm entrectinib	<ol style="list-style-type: none"> 1. Solid tumors (any line of therapy) 2. Positive for NTRK1/ 2/ 3, ROS1 and ALK 3. ROS1 naïve 4. ALK or ROS1 (previously treated w/ crizotinib), CNS-only progression 	Leann Au 3506 2851	Recruitment ongoing
6	QEH	XALT3: Phase 3 Randomized Study Comparing X-396 to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer(NSCLC) Patients	Lung	X-396 or Crizotinib	<ol style="list-style-type: none"> 1. Stage IIIB or IV NSCLC 2. ALK +ve by FISH or IHC 3. No prior TKI treatment (For prior tx, only accept 1 regimen of systemic anticancer therapy) 4. ECOG ≤2 	Kipo Wan 3506 2413	Open
7	QEH	A Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-III A	Lung	AZD9291/Placebo	<ol style="list-style-type: none"> 1. classified post-operatively as Stage IB, II or IIIA on the basis of the pathologic criteria 2. Confirmation that the 	Kipo Wan 3506 2413	Open

		Non-small Cell Lung Carcinoma, following Complete Tumour Resection With or Without Adjuvant Chemotherapy(ADAURA)			tumor harbours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations including T790M		
8	QEH	A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer [Protocol No.: I4T-MC-JVCY]	Lung	Ramucirumab	<ol style="list-style-type: none"> 1. Untreated NSCLC with EGFR Positive (Exon 19 deletion or exon 21 'L858R') 2. Stage IV disease 	Apple Cheung 3506 2414	Open
9	QMH, TMH	A Phase 3, Randomized, Open-label Study Of Lorlatinib (Pf-06463922) Monotherapy Versus Crizotinib Monotherapy In The First-line Treatment Of Patients With Advanced Alk-positive Non-small Cell Lung Cancer	Lung	Lorlatinib	<p>Website: https://clinicaltrials.gov/ct2/show/NCT03052608?term=B7461006&rank=1</p>	/	Open